- Previous Close
0.7732 - Open
0.7600 - Bid 0.7888 x 200
- Ask 0.7987 x 200
- Day's Range
0.7600 - 0.8200 - 52 Week Range
0.5200 - 1.1400 - Volume
3,195,032 - Avg. Volume
607,058 - Market Cap (intraday)
57.699M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3500 - Earnings Date Nov 13, 2024 - Nov 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
www.kezarlifesciences.comRecent News: KZR
View More
Performance Overview: KZR
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KZR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KZR
View MoreValuation Measures
Market Cap
56.41M
Enterprise Value
-90.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.04
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.07%
Return on Equity (ttm)
-51.48%
Revenue (ttm)
7M
Net Income Avi to Common (ttm)
-98.57M
Diluted EPS (ttm)
-1.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
164.18M
Total Debt/Equity (mrq)
11.69%
Levered Free Cash Flow (ttm)
-41.5M
Research Analysis: KZR
View MoreCompany Insights: KZR
KZR does not have Company Insights
Research Reports: KZR
View MoreDaily – Vickers Top Buyers & Sellers for 01/26/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/06/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/23/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.